78.92 USD
+0.41 (+0.52%)
Taking everything into account, RVMD scores 2 out of 10 in our fundamental rating. RVMD was compared to 531 industry peers in the Biotechnology industry. While RVMD seems to be doing ok healthwise, there are quite some concerns on its profitability. RVMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
RVMD had negative earnings in the past year.
In the past year RVMD has reported a negative cash flow from operations.
In the past 5 years RVMD always reported negative net income.
RVMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RVMD's Return On Assets of -26.65% is fine compared to the rest of the industry. RVMD outperforms 70.06% of its industry peers.
RVMD's Return On Equity of -37.58% is fine compared to the rest of the industry. RVMD outperforms 71.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| ROIC | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RVMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RVMD has more shares outstanding
RVMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 12.26 indicates that RVMD is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.26, RVMD belongs to the top of the industry, outperforming 83.99% of the companies in the same industry.
A Debt/Equity ratio of 0.16 indicates that RVMD is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.16, RVMD is doing worse than 65.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 12.26 |
ROIC/WACCN/A
WACC8.77%
2.3 Liquidity
RVMD has a Current Ratio of 8.05. This indicates that RVMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 8.05, RVMD is in the better half of the industry, outperforming 74.39% of the companies in the same industry.
A Quick Ratio of 8.05 indicates that RVMD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.05, RVMD is in the better half of the industry, outperforming 74.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.05 | ||
| Quick Ratio | 8.05 |
3. Growth
3.1 Past
RVMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.01%.
RVMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, RVMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.00% on average per year.
Based on estimates for the next years, RVMD will show a very strong growth in Revenue. The Revenue will grow by 454.63% on average per year.
EPS Next Y-59.96%
EPS Next 2Y-35.33%
EPS Next 3Y-18.97%
EPS Next 5Y14%
Revenue Next Year1279.08%
Revenue Next 2Y959.84%
Revenue Next 3Y770.59%
Revenue Next 5Y454.63%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
RVMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RVMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RVMD's earnings are expected to decrease with -18.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.33%
EPS Next 3Y-18.97%
5. Dividend
5.1 Amount
RVMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:RVMD (12/12/2025, 3:58:04 PM)
78.92
+0.41 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.6%
Inst Owner Change1.75%
Ins Owners1.87%
Ins Owner Change-1.38%
Market Cap15.26B
Revenue(TTM)N/A
Net Income(TTM)-600.09M
Analysts87.41
Price Target81.55 (3.33%)
Short Float %9.39%
Short Ratio7.82
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.02%
Min EPS beat(2)-12.79%
Max EPS beat(2)-11.24%
EPS beat(4)0
Avg EPS beat(4)-9.21%
Min EPS beat(4)-12.79%
Max EPS beat(4)-1.54%
EPS beat(8)1
Avg EPS beat(8)-7.65%
EPS beat(12)4
Avg EPS beat(12)-2.45%
EPS beat(16)6
Avg EPS beat(16)-2.06%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.09%
PT rev (3m)10.17%
EPS NQ rev (1m)-2.07%
EPS NQ rev (3m)-5.48%
EPS NY rev (1m)-4.37%
EPS NY rev (3m)-6.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)25.53%
Revenue NY rev (1m)6.08%
Revenue NY rev (3m)-34.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.55 | ||
| P/tB | 10 | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.17
EYN/A
EPS(NY)-6.54
Fwd EYN/A
FCF(TTM)-4.02
FCFYN/A
OCF(TTM)-3.94
OCFYN/A
SpS0
BVpS8.26
TBVpS7.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.65% | ||
| ROE | -37.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.08%
ROA(5y)-24.01%
ROE(3y)-28.89%
ROE(5y)-28.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 277.69% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.05 | ||
| Quick Ratio | 8.05 | ||
| Altman-Z | 12.26 |
F-Score1
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)158.77%
Cap/Depr(5y)142.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.28%
EPS Next Y-59.96%
EPS Next 2Y-35.33%
EPS Next 3Y-18.97%
EPS Next 5Y14%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1279.08%
Revenue Next 2Y959.84%
Revenue Next 3Y770.59%
Revenue Next 5Y454.63%
EBIT growth 1Y-41.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-68.61%
EBIT Next 3Y-28.97%
EBIT Next 5Y7.47%
FCF growth 1Y-158.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.07%
OCF growth 3YN/A
OCF growth 5YN/A
REVOLUTION MEDICINES INC / RVMD FAQ
What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (RVMD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to RVMD.
Can you provide the valuation status for REVOLUTION MEDICINES INC?
ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (RVMD). This can be considered as Overvalued.
How profitable is REVOLUTION MEDICINES INC (RVMD) stock?
REVOLUTION MEDICINES INC (RVMD) has a profitability rating of 1 / 10.
Can you provide the financial health for RVMD stock?
The financial health rating of REVOLUTION MEDICINES INC (RVMD) is 5 / 10.
Can you provide the expected EPS growth for RVMD stock?
The Earnings per Share (EPS) of REVOLUTION MEDICINES INC (RVMD) is expected to decline by -59.96% in the next year.